{"id":"NCT01604850","sponsor":"Gilead Sciences","briefTitle":"Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06","primaryCompletion":"2013-02","completion":"2013-05","firstPosted":"2012-05-24","resultsPosted":"2014-05-01","lastUpdate":"2014-05-28"},"enrollment":202,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C"],"interventions":[{"type":"DRUG","name":"SOF","otherNames":["SovaldiÂ®","GS-7977","PSI-7977"]},{"type":"DRUG","name":"RBV","otherNames":[]},{"type":"DRUG","name":"Placebo to match SOF","otherNames":[]},{"type":"DRUG","name":"Placebo to match RBV","otherNames":[]}],"arms":[{"label":"SOF+RBV+placebo","type":"EXPERIMENTAL"},{"label":"SOF+RBV","type":"EXPERIMENTAL"}],"summary":"This study was to assess the safety and efficacy of sofosbuvir in combination with ribavirin (RBV) administered for 12 or 16 weeks in participants with genotypes 2 or 3 hepatitis C virus (HCV) infection as assessed by the proportion of participants with sustained virologic response (SVR) 12 weeks after discontinuation of therapy (SVR12).","primaryOutcome":{"measure":"Percentage of Participants Achieving SVR12","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF+RBV+Placebo","deltaMin":51,"sd":null},{"arm":"SOF+RBV","deltaMin":72.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":67,"countries":["United States","Canada","New Zealand","Puerto Rico"]},"refs":{"pmids":["25583164","25040192","23607593"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":103},"commonTop":["Fatigue","Headache","Insomnia","Nausea","Irritability"]}}